<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>Posts | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>Posts</span>
        <span>2024-10-08</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39370772/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Dehydrogenative Coupling Reactions with Guanidino-Functionalized Aromatics</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39370772-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Dehydrogenative coupling (DC) reactions are of importance for the construction of new carbon-element bonds in synthetic organic chemistry. In this work, we report on the synthesis and characterization of several redox-active guanidino-functionalized aromatic molecules (GFAs) for use in DC (C-C and C-O) reactions. In a systematic approach, we first characterize the new DC reagents in all relevant redox and protonation states, and compare their performance in competitive test &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39370902/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">The lysosomal lipid transporter LIMP-2/SCARB2 is part of lysosome-endoplasmic reticulum STARD3-VAPB-dependent contact sites</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39370902-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    SCARB2/LIMP-2 is an abundant lysosomal membrane protein. Previous studies have shown LIMP-2 functions as a virus receptor, a chaperone for lysosomal enzyme targeting, and a lipid transporter. The large luminal domain of LIMP-2 contains a hydrophobic tunnel that enables transport of phospholipids, sphingosine and cholesterol from the lysosomal lumen to the membrane. The question about the fate of the lipids after LIMP-2-mediated transport is largely unexplored. To elucidate whether LIMP-2 is &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39371051/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Survival in Thyroid Cancer in Sweden From 1999 To 2018</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39371051-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The poor survival for anaplastic TC is an extreme contrast to the excellent survival of differentiated TC. As less than 20% of anaplastic cancer patients survived one year, urgent diagnosis and initiation of treatment are important. Facilitated treatment pathways have been instituted in Denmark resulting in improved survival. Anaplastic cancer should be a target of a major research &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39371249/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Sickle Cell Disease</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39371249-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Sickle cell disease (SCD) is among the most frequent hereditary disorders globally and its prevalence in Europe is increasing due to migration &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39371253/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Prolonged Thrombocytopenia and Severe Transfusion Reaction after ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with Chronic Myelomonocytic Leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39371253-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: In case of transfusion reactions against platelet products in major ABO-incompatible allo-HCT patients, isoagglutinin monitoring should be considered and a change in the platelet transfusion protocol may be beneficial in patients presenting high isotiters against recipient&rsquo;s blood &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39371415/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">SoccHealth: a health status examination of former professional football (soccer) players within the German National Cohort</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39371415-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The long-term health effects of football (soccer) have received significant attention in recent years. While brain health is currently the focus of this interest, potential long-term risks or benefits related to cardiovascular and metabolic diseases and cancer are also of interest to sports medicine professionals. However, studies assessing the overall health risks for professional football players remain scarce. We introduce &lsquo;SoccHealth&rsquo;, a satellite project to the German National &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39371421/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241007200552&amp;v=2.18.0.post9&#43;e462414">DGDRP: drug-specific gene selection for drug response prediction via re-ranking through propagating and learning biological network</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39371421-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241007200552-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Introduction: Drug response prediction, especially in terms of cell viability prediction, is a well-studied research problem with significant implications for personalized medicine. It enables the identification of the most effective drugs based on individual genetic profiles, aids in selecting potential drug candidates, and helps identify biomarkers that predict drug efficacy and toxicity.A deeper investigation on drug response prediction reveals that drugs exert their effects by &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39371752/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241007200552&amp;v=2.18.0.post9&#43;e462414">Graph Neural Network-Based Drug Gene Interactions of Wnt/beta-Catenin Pathway in Bone Formation</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39371752-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241007200552-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Introduction The Wnt/β-catenin pathway is crucial for bone formation and remodeling, regulating osteoblast differentiation, bone remodeling, and skeletal homeostasis. Dysregulation of the Wnt/β-catenin pathway is linked to bone-related diseases like osteoporosis, osteoarthritis, and osteosarcoma. The strategies to modulate this pathway include Wnt agonists, inhibitors, and small molecules. Graph neural networks (GNNs) have shown potential in understanding drug-gene interactions, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39372842/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39372842-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    BACKGROUND: Functional neurological disorder (FND) is a common cause of neurological symptoms including paralysis, seizures, and movement disorders. It is often debilitating, is associated with high health and social care costs, and can have a poor prognosis. Functional magnetic resonance imaging (fMRI) has suggested FND is a multi-network disorder; the default mode network (DMN) may be specifically implicated. Converging evidence suggests that other variable mechanisms including &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39372873/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Transoral laser microsurgery for supraglottic carcinomas: results of a prospective multicenter trial (SUPRATOL)</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39372873-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Our prospective multicenter trial shows that, at 12 months post-TLM-SGL +/- R(C)T, 95.5%-98.8% of patients achieved aspiration-free swallowing. Morbidity was higher than previously reported. The rates of permanent tracheostomy and gastrostomy tube placement correspond to previous cohort studies. The 2-year oncologic outcomes are within the reported &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39372928/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241007200552&amp;v=2.18.0.post9&#43;e462414">BioPathNet: Enhancing Link Prediction in Biomedical Knowledge Graphs through Path Representation Learning</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39372928-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241007200552-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Understanding complex interactions in biomedical networks is crucial for advancements in biomedicine, but traditional link prediction (LP) methods are limited in capturing this complexity. Representation-based learning techniques improve prediction accuracy by mapping nodes to low-dimensional embeddings, yet they often struggle with interpretability and scalability. We present BioPathNet, a novel graph neural network framework based on the Neural Bellman-Ford Network (NBFNet), addressing &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373051/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241007200552&amp;v=2.18.0.post9&#43;e462414">scDFN: enhancing single-cell RNA-seq clustering with deep fusion networks</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373051-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241007200552-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Single-cell ribonucleic acid sequencing (scRNA-seq) technology can be used to perform high-resolution analysis of the transcriptomes of individual cells. Therefore, its application has gained popularity for accurately analyzing the ever-increasing content of heterogeneous single-cell datasets. Central to interpreting scRNA-seq data is the clustering of cells to decipher transcriptomic diversity and infer cell behavior patterns. However, its complexity necessitates the application of &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373052/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1x5bM_TNL8gjogAcnslpo2s2PbDe-61JVM2h9yowOYSiZ7Dkrt&amp;fc=20220919211934&amp;ff=20241007200552&amp;v=2.18.0.post9&#43;e462414">Deep learning in template-free de novo biosynthetic pathway design of natural products</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373052-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1x5bm-tnl8gjogacnslpo2s2pbde-61jvm2h9yowoysiz7dkrt-fc-20220919211934-ff-20241007200552-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Natural products (NPs) are indispensable in drug development, particularly in combating infections, cancer, and neurodegenerative diseases. However, their limited availability poses significant challenges. Template-free de novo biosynthetic pathway design provides a strategic solution for NP production, with deep learning standing out as a powerful tool in this domain. This review delves into state-of-the-art deep learning algorithms in NP biosynthesis pathway design. It provides an &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373384/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241007200544&amp;v=2.18.0.post9&#43;e462414">Confirmatory Trials of Accelerated Approval Drugs - Will Imposing Fines Reduce Delays?</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373384-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241007200544-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373386/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241007200544&amp;v=2.18.0.post9&#43;e462414">Addressing Health Care Cost Growth - Why and How States Should Lead</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373386-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241007200544-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373397/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20241007200544&amp;v=2.18.0.post9&#43;e462414">Secondary Syphilis with Osteitis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373397-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20241007200544-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373433/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Testing the Origins of Neutrino Mass with Supernova-Neutrino Time Delay</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373433-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The origin of neutrino masses remains unknown. Both the vacuum mass and the dark mass generated by the neutrino interaction with dark matter (DM) particles or fields can fit the current oscillation data. The dark mass squared is proportional to the DM number density and, therefore, varies on the galactic scale with much larger values around the Galactic Center. This affects the group velocity and the arrival time delay of core-collapse supernovae (SN) neutrinos. This time delay, especially &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373623/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Alcohol consumption and smoking history at time of diagnosis, and risk of colorectal cancer recurrence and mortality: Results from the ColoCare Study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373623-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: No associations were observed between alcohol and smoking at diagnosis and clinical outcomes in this well-annotated longitudinal &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373740/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Peripheral nerve grafting</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373740-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    OBJECTIVE: Peripheral nerve lesions often lead to significant and permanent loss of motor and sensory function. The aim of peripheral nerve grafting is to bridge nerve &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39373835/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Investigation of inert gas washout methods in a new numerical model based on an electrical analogy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39373835-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Inert gas washout methods have been shown to detect pathological changes in the small airways that occur in the early stages of obstructive lung diseases such as asthma and COPD. Numerical lung models support the analysis of characteristic washout curves, but are limited in their ability to simulate the complexity of lung anatomy over an appropriate time period. Therefore, the interpretation of patient-specific washout data remains a challenge. A new numerical lung model is presented in &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374011/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Critical Impact of Working Distance on OCT Imaging: Correction of Optical Distortion and Its Effects on Measuring Retinal Curvature</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374011-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: Correcting optical distortion in OCT imaging significantly mitigates the influence of WD on BM layer curvature, enabling a more accurate analysis of posterior eye morphology, especially when variations in WD are &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374017/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy for Advanced Hematologic Malignant Neoplasms: A Meta-Analysis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374017-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND RELEVANCE: This meta-analysis found a low prevalence of ventricular arrhythmia, myocardial infarction, and cardiovascular death among CAR T-cell recipients over a short-term to midterm follow-up. Left ventricular dysfunction and supraventricular arrhythmia were the most commonly reported cardiovascular complications, suggesting that cardiovascular surveillance strategies should focus on decreases in ejection fraction and supraventricular &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374195/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20241007200555&amp;v=2.18.0.post9&#43;e462414">Diagnosing skin neglected tropical diseases with the aid of digital health tools: A scoping review</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374195-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20241007200555-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Delays in diagnosis and detection of skin neglected tropical diseases (NTDs) pose obstacles to prompt treatment, which is crucial in preventing disability. Recent developments in digital health have given rise to approaches that could increase access to diagnosis in resource-poor areas affected by skin NTDs. This scoping review provides an overview of current digital health approaches that aim to aid in the diagnosis of skin NTDs and provides an insight into the diverse functionalities &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374519/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241007200551&amp;v=2.18.0.post9&#43;e462414">How I diagnose and treat cardiorespiratory complications of transfusion</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374519-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241007200551-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Cardiorespiratory complications after blood transfusion are the leading cause of transfusion related morbidity and mortality world-wide. Transfusion-related acute lung injury (TRALI) and transfusion associated circulatory overload (TACO) form the top two most frequently reported cardiorespiratory complications, both with clear pathophysiology-based treatment algorithms. In the past decades translational research has increased understanding of mechanisms in place including patient and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374520/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241007200551&amp;v=2.18.0.post9&#43;e462414">How I treat Blastic Plasmacytoid Dendritic Cell Neoplasm</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374520-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241007200551-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Historically, treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN) were limited to conventional chemotherapy, adopted from regimens used to treat acute myeloid or acute lymphoblastic leukemias, or lymphomas. Nowadays, a novel therapy targeting CD123 is available to treat BPDCN. Yet, regardless of treatment choice, achieving a first complete remission (CR1) represents the main goal of therapy, because it represents the best opportunity to prolong survival in BPDCN, &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374521/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241007200551&amp;v=2.18.0.post9&#43;e462414">Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374521-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241007200551-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Dasatinib is effective treatment for Philadelphia chromosome-positive (Ph+) acute leukemia but some patients develop resistance. Combination treatment with dasatinib and asciminib, an allosteric inhibitor of BCR::ABL1, may deepen responses and prevent the emergence of dasatinib-resistant clones. In this phase 1 study (NCT03595017), 24 adults with Ph+ acute lymphoblastic leukemia (ALL, n=22; p190, n=16; p210, n=6) and chronic myeloid leukemia in lymphoid blast crisis (CML-LBC, n=2) were &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374522/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241007200551&amp;v=2.18.0.post9&#43;e462414">Single-cell analysis of the multiple myeloma microenvironment after gamma-secretase inhibition and CAR T-cell therapy</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374522-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241007200551-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Chimeric antigen receptor (CAR) T-cells and bispecific antibodies (BsAb) targeting B-cell maturation antigen (BCMA) have significantly advanced the treatment of relapsed and refractory multiple myeloma (MM). Resistance to BCMA-targeting therapies, nonetheless, remains a significant challenge. BCMA shedding by gamma-secretase is a known resistance mechanism, and preclinical studies suggest that inhibition may improve anti-BCMA therapy. Leveraging a phase I clinical trial of the &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374533/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241007200551&amp;v=2.18.0.post9&#43;e462414">Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374533-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241007200551-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Iptacopan, a novel oral Factor B inhibitor, recently obtained FDA approval for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized by persistent complement-mediated hemolytic anemia. The standard-of-care (SOC) has traditionally relied on complement C5 inhibitors eculizumab and ravulizumab, which are limited by persistent anemia from extravascular hemolysis and requirement for intravenous infusion. Recent publication of phase 3 studies in this arena &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374534/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241007200551&amp;v=2.18.0.post9&#43;e462414">How I use Maintenance Therapy in Acute Myeloid Leukemia</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374534-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241007200551-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    Outcomes for acute myeloid leukemia have improved significantly in the last decade with the approval of novel therapeutics targeting diverse vulnerabilities of leukemic cells, expanded access to stem cell transplantation, and improved safety of transplantation. While attainment of initial remission is now an expected outcome in most AML patients receiving intensive or non-intensive induction regimens, maintaining long-term remission and decreasing the risk of relapse remain critical &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39374535/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20241007200551&amp;v=2.18.0.post9&#43;e462414">Follicular lymphoma comprises germinal center-like and memory-like molecular subtypes with prognostic significance</a></h1>
  <div class="date-author">
    
    <span class="date">2024-10-07</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39374535-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20241007200551-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    A robust prognostic and biological classification for newly diagnosed follicular lymphoma (FL) using molecular profiling remains challenging. FL tumors from patients treated in the RELEVANCE trial with rituximab-chemotherapy (R-chemo) or rituximab-lenalidomide (R2) were analyzed using RNA-sequencing, DNA-sequencing, immunohistochemistry (IHC) and/or fluorescence in situ hybridization. Unsupervised gene clustering identified two gene expression signatures (GS) enriched with normal memory &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

